Adherence and retention of female injection drug users in a phase III clinical trial in inner city Baltimore

Richard D. Semba, Erin P. Ricketts, Shruti F. Mehta, Gregory D. Kirk, Carl Latkin, Noya Galai, David Vlahov

Research output: Contribution to journalArticlepeer-review

Abstract

Adherence and retention of female injection drug users (IDUs) in clinical trials are not well known and were evaluated among 458 female IDUs in a clinical trial in Baltimore. Of all, 62.9% were adherent to visits (attended ≥ 80% of visits). Of women with ≥ 1 visit after enrollment, 76% were adherent to treatment (took ≥ 80% of pills); 27.7% were lost to follow-up (missed ≥ 3 consecutive visits). Women nonadherent to visits were younger and less likely to be on methadone. Women lost to follow-up were younger, more often white, not on methadone, and injecting drugs daily. Fair-moderate adherence to visits and treatment occurs among female IDUs in a clinical trial.

Original languageEnglish
Pages (from-to)71-80
Number of pages10
JournalAmerican Journal of Drug and Alcohol Abuse
Volume33
Issue number1
DOIs
StatePublished - Jan 2007

Bibliographical note

Funding Information:
This study was supported by the National Institute on Nursing Research (R01 NR009478) and the National Institute on Drug Abuse (R01 DA15022).

Keywords

  • Adherence
  • Clinical trial
  • HCV
  • HIV
  • Injection drug user
  • Minority

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology
  • Medicine (miscellaneous)

Cite this